Avacta Group plc announces positive outcome of proof-of-concept study with Glythera and follow-on drug development partnership
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the develo...
Continue Reading →
